CLINICAL_TRIALS trial_result · 2022-07-05

Clinical Trial Update: miRNAs, Suicide, and Ketamine - Plasma Exosomal microRNAs as Novel Biomarkers for Suicidality and Treatment Outcome [Phase 2]

Phase 2 clinical trial investigating plasma exosomal microRNAs as biomarkers for suicidality and treatment outcome in major depressive disorder.

Upgrade for the full analysis, importance score, and drug timeline.

Sponsor: University of Alabama at Birmingham | Conditions: Major Depressive Disorder | Phase 2 | Status: COMPLETED | Results posted: 2022-07-05